|
Lug 6, 2016
Deutetrabenazine for Treatment of Chorea in Huntington Disease
In this issue of JAMA, the Huntington Study Group (HSG), First-HD study investigators, reports findings from a randomized trial examining use of a deuterated form of tetrabenazine, called deutetrabenazine, for treatment of chorea in patients with Huntington disease.1 Tetrabenazine, a vesicular monoamine transporter type 2 inhibitor that depletes monoamines including dopamine, is used worldwide for the treatment of chorea and dystonia. Tetrabenazine was approved by the US Food and Drug Administration (FDA) for the treatment of chorea in Huntington disease, based on a prior HSG study.2
|
|
Lug 15, 2016
Giving Huntington’s disease the one-two punch
Mass. General-led study identifies molecular compound with two neuroprotective activitiesAmajor, multi-institutional study based at Harvard-affiliated Massachusetts General Hospital (MGH) has identified a promising treatment strategy for Huntington’s disease (HD).
|
|
Lug 14, 2016
9th EHDN Plenary Meeting 2016
The EHDN2016 Plenary Meeting will take place at the World Forum in The Hague, The Netherlands, 16-18 September 2016.
|
|
Lug 13, 2016
Multiple Genetic Variations of Huntington’s Disease Identified
An array of various phenocopies with multiple etiologies that are not associated with the main chromosomal mutation responsible forHuntington’s disease (HD) can also produce HD symptoms, according to a study reported inJAMA Neurology.1
|
|
|
|
|
